

THE NEGATIVE DIRECT EFFECT OF DEPRESSIVE SYMPTOMS ON PREP ADHERENCE AMONG HIGH-RISK SOUTH AFRICAN WOMEN IN HPTN 067

Jennifer Velloza^{1,2} ■ Renee Heffron^{1,2} ■ K. Rivet Amico³ ■ Ali Rowhani-Rahbar² ■ James P. Hughes⁴ ■ Maoji Li⁴ ■ Bonnie Dye⁵ ■ Connie Celum^{1,2,6} ■ Linda-Gail Bekker⁷ ■ Robert M. Grant⁸

¹University of Washington, Department of Global Health, Seattle, USA; ²University of Washington, Department of Epidemiology, Seattle, USA; ³University of Michigan, Department of Health Behavior Health Education, Ann Arbor, USA; ⁴Fred Hutchinson Cancer Research Center, Seattle, USA; ⁵FHI 360, Durham, USA; ⁶University of Washington, Department of Medicine, Seattle, USA; ⁷The Desmond Tutu HIV Centre, Cape Town, RSA; ⁸University of California at San Francisco, San Francisco, USA

BACKGROUND


- Daily oral pre-exposure prophylaxis (PrEP) is a highly efficacious HIV prevention strategy when taken regularly
- There remains a need to identify modifiable factors to improve PrEP adherence particularly for women at high risk of HIV
- Depression affects 30-50% of women in sub-Saharan Africa, and is a known barrier to healthcare engagement and daily medication adherence (e.g., contraceptives, ART)
 - May affect PrEP use through other psychosocial factors including anticipated stigma around PrEP, social support to use PrEP, and optimism about PrEP's effectiveness



OBJECTIVE

- Examine whether depression is linked to low PrEP adherence among women in Cape Town, South Africa
- Explore whether a relationship between depression and PrEP adherence is mediated by stigma, social support, or optimism about PrEP effectiveness

Figure 1. Directed acyclic graph depicting relationships between study variables



Depressive symptoms are a barrier to PrEP adherence for women and there was no evidence of mediation by stigma, social support, or optimism about PrEP.



METHODS

STUDY SAMPLE

- South African women participating in HPTN 067/ADAPT randomized trial of intermittent and daily PrEP
 - Data collection and follow-up concluded in 2014
 - Study visits at weeks 0, 4, 12, and 24 post randomization
- PrEP adherence: ≥80% expected doses in the month prior to week 24 study visit measured via Wisepill™
 - Wisepill™ data adjusted via weekly interviews to assess whether participant took a pill corresponding with the device opening and whether they took other PrEP doses (Bekker et al., *Lancet HIV*, 2018)
- Likely depression exposure: CES-D score ≥16 measured by CASI at baseline study visit
- Potential mediators of relationship between likely depression and PrEP adherence: PrEP stigma, social support, optimism about PrEP effectiveness measured via scales and categorized into binary variables

RESULTS

SAMPLE CHARACTERISTICS

- 174 women included in analysis sample (>90% visit attendance)
 - 57 (32.8%) in daily PrEP arm; 58 (33.3%) were in time-driven dosing arm; 59 (33.9%) were in event-driven arm
- 79 (45.4%) had CES-D scores ≥16 at baseline
- 87 (50.0%) ≤25 years old
- 60 (34.5%) completed secondary education
- 16 (9.2%) reported transactional sex
- 76 (43.7%) reported high or unknown chance of HIV infection
- CES-D score ≥16 was associated with older age, less education, fewer vaginal or anal sex acts in the 3 months prior to enrollment, greater report of transactional sex, greater report of drug and alcohol use, and higher HIV risk perceptions at baseline (p<0.05 for all)



TABLE 1. Total effect of association between depression and PrEP adherence

	Visits with high PrEP adherence ¹ (N=87; 53.0%)	Relative scale ²	
		aRR (95% CI)	p-value
Depressive symptoms	35 (44.3%)	0.79 (0.63, 0.99)	0.05
No symptoms	52 (54.7%)	REF	REF

aRR= adjusted relative risk; 95% CI= 95% confidence interval
¹Participants were considered adherent to PrEP if their adjusted Wisepill data indicated that they had taken ≥80% of expected pills at the Week 24 study visit
²Stabilized inverse probability weights account for confounding by the sets of baseline (age, marital status, education, alcohol and drug use) and longitudinal confounders (any unprotected sex, HIV risk perceptions; weight mean=0.99; range=0.47-2.38)

PRIMARY STATISTICAL ANALYSES

- Marginal structural model to estimate *total effect of depression on PrEP adherence*
 - Inverse probability weights estimated with logistic regression with age, marital status, education, alcohol and drug use (baseline confounders) and HIV risk perception and condomless sex (mediator-outcome confounders affected by the exposure)
 - Models fit with a log link, binomial distribution, and robust standard errors
- Marginal structural models to quantify the magnitude of association between depression and PrEP adherence that remains after removing downstream influence of each mediator (*controlled direct effect of depression on PrEP adherence*)
 - Separate weights for exposure and mediator, multiplied together to calculate total weight
- Fit interaction terms for exposure and mediators to examine moderated-mediation

TABLE 2. Controlled direct effect estimates for the association¹ for each mediator

Exposure	Mediator	Outcome	Relative scale ²	
			aRR (95% CI)	p-value
Depression	Stigma	Adherence	0.74 (0.51, 0.97)	0.02
Depression	Social support	Adherence	0.77 (0.57, 1.03)	0.07
Depression	PrEP optimism	Adherence	0.75 (0.55, 0.99)	0.05

aRR= adjusted relative risk; 95% CI= 95% confidence interval
¹Participants were considered adherent to PrEP if their adjusted Wisepill data indicated that they had taken ≥80% of expected pills at the Week 24 study visit
²Stabilized inverse probability weights account for confounders (same set of baseline and longitudinal confounders included for Table 1) and mediators

DISCUSSION

- In this open-label randomized evaluation of PrEP dosing regimens in South Africa, depression was highly prevalent and women with depression were less adherent to PrEP
 - Anticipated stigma, instrumental social support, and optimism about PrEP were not mediators of this association
 - Similar finding to other recent analyses showing negative influence of depression on PrEP adherence for women
- Mechanism for the relationship between depression and PrEP adherence is not well understood:
 - Lower healthcare engagement and reduced motivation to take PrEP?
 - Changes in sexual behavior?
- Need for future interventions to build mental health screening platforms and treatment approaches integrated with PrEP service delivery for women
 - Potential to improve mental health and maximize public health impact of PrEP for women
- Additional research needed on mechanisms for relationship between depression and PrEP adherence

ACKNOWLEDGMENTS

HPTN 067 is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) under Cooperative Agreements UM1-AI068619, UM1-AI068617, and UM1-AI068613, with funding from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Additional funding is provided by the International Initiative for Impact Evaluation (3ie) with support from the Bill & Melinda Gates Foundation, as well as by NIAID, the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH), all part of the U.S. National Institutes of Health (NIH). This work was also supported in part by the Emory-CDC HIV/AIDS Clinical Trials Unit award number UM1AI069418 from the NIH (NIAID). JV was supported by the NIMH of the NIH (grant F31 MH113420).

The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID, NIMH, NIDA, PEPFAR, 3ie, or the Bill & Melinda Gates Foundation.